Eichner Amy, Lewis Laura A, Leonard Bridget, Wagoner Ryan M Van, Eichner Daniel, Fedoruk Matthew N
United States Anti-Doping Agency, Colorado Springs, CO, United States.
Sports Medicine and Research Testing Laboratory, Salt Lake City, UT, United States.
Front Sports Act Living. 2021 Nov 18;3:692244. doi: 10.3389/fspor.2021.692244. eCollection 2021.
This paper describes nine instances of positive anti-doping tests that could be accounted for by the use of permitted generic prescription drugs contaminated with diuretics, which are prohibited in sport at all times under the WADA Prohibited List. The contamination levels found in the medications are reported and were below FDA limits for manufacturers that are based primarily on safety considerations. These cases demonstrate that great care must be taken to identify the source of low-level anti-doping positives for diuretics reported by WADA-accredited laboratories, and possibly other prohibited substances as well, in order to avoid sanctioning innocent athletes. An evaluation of the cases in this paper supports an approach which establishes a laboratory minimum reporting level (MRL) for diuretics found most commonly in medications. A global consensus after extensive review of similar anti-doping cases has resulted in implementation of a recently announced solution regarding potential diuretic contamination cases.
本文描述了9例阳性兴奋剂检测案例,这些案例可归因于使用了被利尿剂污染的允许使用的普通处方药,而利尿剂在世界反兴奋剂机构(WADA)的《禁用清单》中在任何时候都是体育赛事中被禁止的。报告了在药物中发现的污染水平,这些水平低于主要基于安全考虑的FDA对制造商的限制。这些案例表明,必须格外小心地确定WADA认可实验室报告的低水平利尿剂阳性结果以及可能的其他违禁物质的来源,以避免制裁无辜的运动员。本文对这些案例的评估支持了一种方法,即针对药物中最常见的利尿剂确定实验室最低报告水平(MRL)。在对类似的反兴奋剂案例进行广泛审查后达成的全球共识,促成了最近宣布的关于潜在利尿剂污染案例的解决方案的实施。